- Home
- FTFT vs BCDA Comparison
FTFT vs BCDA Comparison
Compare FTFT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- BCDA
- Stock Information
- Founded
- FTFT N/A
- BCDA N/A
- Country
- FTFT United States
- BCDA United States
- Employees
- FTFT N/A
- BCDA N/A
- Industry
- FTFT Business Services
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- BCDA Health Care
- Exchange
- FTFT Nasdaq
- BCDA Nasdaq
- Market Cap
- FTFT 11.0M
- BCDA 11.3M
- IPO Year
- FTFT N/A
- BCDA N/A
- Fundamental
- Price
- FTFT $2.06
- BCDA $1.46
- Analyst Decision
- FTFT
- BCDA Strong Buy
- Analyst Count
- FTFT 0
- BCDA 1
- Target Price
- FTFT N/A
- BCDA $25.00
- AVG Volume (30 Days)
- FTFT 131.6K
- BCDA 582.6K
- Earning Date
- FTFT 11-18-2025
- BCDA 11-12-2025
- Dividend Yield
- FTFT N/A
- BCDA N/A
- EPS Growth
- FTFT N/A
- BCDA N/A
- EPS
- FTFT N/A
- BCDA N/A
- Revenue
- FTFT $2,368,206.00
- BCDA N/A
- Revenue This Year
- FTFT N/A
- BCDA N/A
- Revenue Next Year
- FTFT N/A
- BCDA N/A
- P/E Ratio
- FTFT N/A
- BCDA N/A
- Revenue Growth
- FTFT N/A
- BCDA N/A
- 52 Week Low
- FTFT $1.01
- BCDA $1.00
- 52 Week High
- FTFT $5.70
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- FTFT 45.45
- BCDA 45.81
- Support Level
- FTFT $2.00
- BCDA $1.30
- Resistance Level
- FTFT $2.37
- BCDA $1.42
- Average True Range (ATR)
- FTFT 0.18
- BCDA 0.11
- MACD
- FTFT -0.01
- BCDA 0.03
- Stochastic Oscillator
- FTFT 14.29
- BCDA 58.06
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).